Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 2

The Lancet Haematology

Tisagenlecleucel and huCART19 are active at clearing CNS disease and maintaining durable remissions in children and young adults with CNS relapsed or refractory B-cell acute lymphocytic leukaemia or lymphocytic lymphoma, without increasing the risk of severe neurotoxicity; although care should be taken in the timing of therapy and disease control to mitigate this risk. These preliminary findings...

  • Although CNS disease was excluded from initial trials of CART in ALL, this retrospective review shows CART is effective in clearing CNS disease and is not associated with increased risk of neurotoxicity.